Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$1.52 +1.3%	$1.66	$1.10 ▼ $4.10	$56.09M	-0.95	12,230 shs	4,448 shs
DSGN Design Therapeutics	$3.98 -1.0%	$3.81	$2.60 ▼ $7.77	$225.95M	1.56	177,220 shs	67,769 shs
ELDN Eledon Pharmaceuticals	$3.70 -1.3%	$3.06	$2.38 ▼ $5.54	$221.56M	-0.16	336,430 shs	376,222 shs
TVGN Semper Paratus Acquisition	$1.23 -0.8%	$1.23	$0.26 ▼ $3.09	$226.19M	-0.73	5.10 million shs	3.31 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	0.00%	-5.55%	+3.40%	-21.04%	-55.29%
DSGN Design Therapeutics	0.00%	+1.53%	+6.42%	+10.86%	-2.21%
ELDN Eledon Pharmaceuticals	0.00%	+8.19%	+36.03%	+24.16%	+37.04%
TVGN Semper Paratus Acquisition	0.00%	+3.36%	+2.50%	+31.93%	+54.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANL Adlai Nortye	1.8256 of 5 stars	3.0	5.0	1.8	0.0	0.0
DSGN Design Therapeutics	0.5951 of 5 stars	1.0	1.0	2.1	2.5	0.6
ELDN Eledon Pharmaceuticals	2.0341 of 5 stars	3.5	1.0	3.3	1.7	0.0
TVGN Semper Paratus Acquisition	3.6458 of 5 stars	3.5	5.0	0.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANL Adlai Nortye	2.00	Hold	$9.00	492.11% Upside
DSGN Design Therapeutics	2.00	Hold	$4.00	0.50% Upside
ELDN Eledon Pharmaceuticals	3.00	Buy	$9.00	143.24% Upside
TVGN Semper Paratus Acquisition	3.00	Buy	$10.00	713.01% Upside

Current Analyst Ratings Breakdown

Latest ANL, TVGN, ELDN, and DSGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ELDN Eledon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$9.00
6/18/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/2/2025	ANL Adlai Nortye	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/27/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/12/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/29/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/21/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANL Adlai Nortye	$5M	11.22	N/A	N/A	$0.69 per share	2.20
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$4.28 per share	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$1.98 per share	N/A
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	($0.09) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANL Adlai Nortye	-$51.87M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/8/2025 (Estimated)
DSGN Design Therapeutics	-$49.59M	-$0.99	N/A	N/A	N/A	N/A	-22.85%	-22.02%	8/4/2025 (Estimated)
ELDN Eledon Pharmaceuticals	-$36.18M	-$2.10	N/A	N/A	N/A	N/A	-79.54%	-41.62%	8/18/2025 (Estimated)
TVGN Semper Paratus Acquisition	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-934.56%	8/4/2025 (Estimated)

Latest ANL, TVGN, ELDN, and DSGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2025	Q2 2025	ELDN Eledon Pharmaceuticals	-$0.23	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q1 2025	DSGN Design Therapeutics	-$0.32	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	DSGN Design Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A
5/14/2025	Q1 2025	ELDN Eledon Pharmaceuticals	-$0.28	-$0.08	+$0.20	-$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANL Adlai Nortye	0.02	1.41	1.41
DSGN Design Therapeutics	N/A	28.37	28.37
ELDN Eledon Pharmaceuticals	N/A	13.90	13.91
TVGN Semper Paratus Acquisition	N/A	0.35	0.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANL Adlai Nortye	35.21%
DSGN Design Therapeutics	56.64%
ELDN Eledon Pharmaceuticals	56.77%
TVGN Semper Paratus Acquisition	N/A

Insider Ownership

Company	Insider Ownership
ANL Adlai Nortye	N/A
DSGN Design Therapeutics	31.20%
ELDN Eledon Pharmaceuticals	12.30%
TVGN Semper Paratus Acquisition	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANL Adlai Nortye	127	36.90 million	N/A	Not Optionable
DSGN Design Therapeutics	40	56.77 million	39.06 million	Optionable
ELDN Eledon Pharmaceuticals	10	59.88 million	52.52 million	Optionable
TVGN Semper Paratus Acquisition	3	183.89 million	49.21 million	N/A

ANL, TVGN, ELDN, and DSGN Headlines

Recent News About These Companies

Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides

July 18 at 12:36 PM | globenewswire.com

Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

July 17, 2025 | globenewswire.com

Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch

July 16, 2025 | globenewswire.com

Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs

July 14, 2025 | globenewswire.com

Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation

July 10, 2025 | globenewswire.com

Tevogen Bio Holdings Inc News (TVGN) - Investing.com

July 8, 2025 | investing.com

Semper Paratus Acquisition (NASDAQ:TVGN) Shares Down 2.4% - Here's Why

July 2, 2025 | marketbeat.com

Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters

June 30, 2025 | globenewswire.com

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

June 18, 2025 | globenewswire.com

Tevogen Bio

June 17, 2025 | thepharmaletter.comT

Tevogen Bio Expands Headquarters To Support Growth In AI And Generics & Biosimilars Initiatives

June 12, 2025 | nasdaq.com

Tevogen Bio Expands Headquarters to Enhance R&D and Operational Efficiency with Support from Microsoft

June 10, 2025 | nasdaq.com

Tevogen Bio doubles Warren HQ footprint for AI expansion

June 10, 2025 | njbiz.comN

Ambitious Tevogen makes expansion announcement

June 10, 2025 | thepharmaletter.comT

Ryan H. Saadi Sells 1,438,206 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock

June 10, 2025 | insidertrades.com

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives

June 9, 2025 | globenewswire.com

tevogen bio expands office lease in new jersey with key amendment

June 5, 2025 | investing.com

Tevogen Bio breidt kantoorruimte uit in New Jersey met belangrijke wijziging

June 4, 2025 | nl.investing.com

Tevogen Bio breidt AI-initiatief uit voor ontwikkeling immunotherapie

June 1, 2025 | nl.investing.com

Tevogen Bio Holdings Inc. Unveils Tevogen.AI™ Initiative to Enhance Immunotherapy Development with Advanced AI Technologies

May 30, 2025 | quiverquant.comQ

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

May 30, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo Lead
By Gabriel Osorio-Mazilli | July 3, 2025
View Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo Lead

ANL, TVGN, ELDN, and DSGN Company Descriptions

Adlai Nortye NASDAQ:ANL

$1.52 +0.02 (+1.33%)

Closing price 07/18/2025 03:24 PM Eastern

Extended Trading

$1.52 0.00 (0.00%)

As of 07/18/2025 05:36 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Design Therapeutics NASDAQ:DSGN

$3.98 -0.04 (-1.00%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.98 0.00 (-0.13%)

As of 07/18/2025 04:04 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Eledon Pharmaceuticals NASDAQ:ELDN

$3.70 -0.05 (-1.33%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.82 +0.12 (+3.35%)

As of 07/18/2025 07:17 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Semper Paratus Acquisition NASDAQ:TVGN

$1.23 -0.01 (-0.81%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.23 0.00 (0.00%)

As of 07/18/2025 07:58 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time